[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-tachycardia-v-tach\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-tachycardia-v-tach":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100588182","imaging-and-treatment-planning-for-cardiac-radioablation-100588182",false,"NCT06938074","Imaging and Treatment Planning for Cardiac Radioablation","ITPCR","Inclusion Criteria\n\n* Ischemic cardiomyopathy with monomorphic VT\n* Referred by cardiologists\n* 18 years of age or older Exclusion Criteria\n* • Polymorphic ventricular tachycardia\n* Ventricular fibrillation\n* Pregnant or breastfeeding or planning to become pregnant or breastfeed during the study\n* Estimated glomerular filtration rate ≤ 30 mL\u002Fmin\u002F1.73m2\n* Previous allergic reaction to CT contrast agent Note that participants with contraindications for MRI can still be enrolled in this study but will not undergo MRI parts of this protocol.","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cardiac radioablation is a new treatment for ventricular tachycardia (VT), which uses beams of radiation to treat heart scar that causes VT. To identify the scar areas, magnetic resonance imaging (MRI) and computed tomography (CT) imaging are often used. These are both types of medical imaging that allow clinicians to examine scar area without having to do invasive surgery.\n\nResearchers have developed new heart imaging protocols using both MRI and CT. Their MRI protocol method can now spot both dense and scattered scar tissue. The CT protocol combines multiple different types of scans into a single appointment and uses a special scanner that captures the motion of the heart. For this study, patients will undergo CT and MRI imaging according to these new imaging protocols.\n\nWith this study, researchers aim to show that these new imaging protocols can be undergone by patients with ventricular tachycardia and can be used to identify scar. Researchers will also use these scans to make radiation treatment plans to identify which types of treatment can be delivered safely to patients.",[26,27,28],"Ventricular Tachycardia, Monomorphic","Ventricular Tachycardia (V-Tach)","Ischemia, Myocardial",[30,31,32,33,34,35],"Cardiac radioablation","Stereotactic arrhythmia radioablation","Ischemic fibrosis","Late iodine enhancement CT","CT perfusion","Late gadolinium enhanced MRI","NOT_YET_RECRUITING","2025-09-22",{"date":39,"type":40},"2025-09-26","ACTUAL",{"date":42,"type":20},"2025-11-01",{"date":44,"type":20},"2026-09-01",{"name":46,"class":47},"Stewart Gaede","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":48},"100594316","stereotactic-radiosurgery-as-second-line-therapy-for-ventricular-tachycardia-100594316","NCT07017855","Stereotactic Radiosurgery as Second-line Therapy for Ventricular Tachycardia","STAR-4VT","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of enrollment.\n2. Presence of structural heart disease (SHD) of either ischemic or non-ischemic etiology.\n3. Implanted ICD or CRT-D device for primary or secondary prevention of sudden cardiac death (SCD).\n4. History of at least one endocardial CA procedure targeting a substrate of monomorphic sVT.\n5. Recurrence of at least one clinically significant and symptomatic episode of monomorphic sVT.\n6. Optimal pharmacological treatment of underlying SHD, including maximally tolerated doses of guideline-recommended heart failure therapies and appropriate antiarrhythmic management.\n7. Provision of written informed consent prior to study participation.\n\nExclusion Criteria:\n\n1. Reversible cause of sVT recurrence, particularly acute coronary syndrome (ACS), acute myocarditis, or lead-related infective endocarditis (LDIE).\n2. Myocardial infarction (MI) or cardiac surgery within the last 40 days.\n3. Idiopathic sVT unrelated to SHD or sVT associated with genetically determined channelopathies.\n4. Ongoing or persistently recurrent hemodynamically unstable sVT until clinical stabilization is achieved.\n5. Acute decompensation of heart failure, classified as New York Heart Association (NYHA) Class IV, until clinical stabilization is achieved.\n6. Worsening angina, classified as Canadian Cardiovascular Society (CCS) Class III or IV until coronary diagnostic evaluation and clinical stabilization are completed.\n7. A mobile thrombus within the left ventricle (LV).\n8. Presence of a left ventricular assist device (LVAD).\n9. Presence of comorbidities or known risk factors for CA complications that, in the judgment of the electrophysiologist, constitute a contraindication to the procedure for safety reasons.\n10. Active, uncontrolled malignancy and\u002For chemotherapy or immunotherapy administered or planned within 1 month of the scheduled ablation procedure.\n11. Features of an active systemic, pulmonary, or pericardial inflammatory process requiring systemic treatment (disease-modifying therapies, corticosteroids, immunosuppressants) within the past 6 months.\n12. Presence of comorbidities or known risk factors for radiotherapy complications that, in the judgment of the radiation oncologist, constitute a contraindication to STAR for safety reasons.\n13. Pregnancy or breastfeeding.\n14. Systemic disease that limits the probability of survival to less than 1 year\n15. Other comorbidities, addictions, or social indications that, in the investigator's opinion, would preclude practical cooperation or otherwise disqualify the patient from participation in the clinical study.\n16. Refusal to participate or lack of written informed consent for study participation.",{"count":57,"type":20},150,[23],"The aim of the study is to compare the efficacy and safety of treating recurrent sustained Ventricular Tachycardia (sVT) after prior Catheter Ablation (CA) in patients with Implanted Cardioverter-Defibrillator (ICD) between re-do of conventional endocardial CA and Stereotactic Arrhythmia Radioablation (STAR).",[26,61,62,27,63,64,65,66],"Ventricular Tachycardia, Sustained","Ventricular Tachycardia (VT)","Stereotactic Body Radiation Therapy (SBRT)","Stereotactic Techniques","Stereotactic Radiation","Cardioverter-Defibrillators, Implantable",[68,69,70,71,72,73],"Ventricular Tachycardia","VT","Stereotactic Arrhythmia Radioablation","STAR","Implanted Cardioverter-Defibrillator","ICD","2025-06-04",{"date":76,"type":40},"2025-06-12",{"date":78,"type":20},"2025-07-01",{"date":80,"type":20},"2028-11-01",{"name":82,"class":47},"Medical University of Silesia",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":48},"100575220","proton-radiosurgery-for-the-treatment-of-malignant-ventricular-tachyarrhythmias-100575220","NCT06769451","Proton Radiosurgery for the Treatment of Malignant Ventricular Tachyarrhythmias","Radiosurgery With proTOns for the Treatment of VEntricular maLignant Tachyarrhytmias (TOVEL Study)","TOVEL","Inclusion Criteria:\n\n1. age ≥ 40 years\n2. carrier of ICD\u002FCRT-D or S-ICD\n3. episodes of ventricular tachycardia\u002Fventricular fibrillation requiring defibrillator intervention (shock or ATP) which are:\n\n   * refractory to maximal drug therapy;\n   * recurrent (at least 3 episodes in the previous 6 months);\n4. patients with contraindications to a conventional ablative strategy, in relation to the high risk associated with the procedure due to the severity of the heart disease and\u002For the presence of comorbidities or patients who have already undergone ablation, in the presence of an arrhythmogenic substrate refractory to or unsuitable for an interventional approach or patients who refuse transcatheter ablative attempts due to high intraoperative risk in relation to the patient's characteristics.\n5. Left ventricular ejection fraction ≥ 20%.\n\nExclusion Criteria:\n\n1. inability to express informed consent\n2. previous thoracic radiotherapy (RT) with cardiac involvement\n3. active myocardial ischemia\n4. recent cardiac revascularization (\\\u003C 120 days)\n5. hemodynamic instability (cardiogenic shock, NYHA class IV)\n6. contraindication to radiosurgery (e.g., due to artifacts or other technical reasons)\n7. lack of patient cooperation in pre-procedural investigations\n8. ICD malfunction\n9. severe comorbidity with prognosis \\\u003C 12 months\n10. pregnancy","40 Years",{"count":93,"type":20},21,[23],"Ventricular arrhythmias (VAs) are the leading cause of sudden cardiac death (SCD) worldwide. The implantable defibrillator (ICD) increases survival in patients at risk of VA, with data of superiority to antiarrhythmic drugs. Nevertheless, the ICD cannot prevent VAs, and shocks delivered by the device (appropriate and inappropriate) negatively impact patients' quality of life. Transcatheter ablation (TCA) is the percutaneous therapy that can eliminate VAs and prevent any recurrence. TCA is the state of the art for the treatment of drug-unresponsive VAs in patients with structural heart disease, but the prevalence of recurrence remains high (between 30% and 60%). For these reasons, several reports have recently appeared in the literature proposing a new solution for the treatment of VAs in which the use of external-beam body radiotherapy with stereotactic-radiosurgical technique (SBRT) is described. SBRT represents a rapid, noninvasive approach based on the delivery of high radiation doses of photons (25 Gy in a single fraction) to a precise location in cardiac tissue.\n\nSBRT has entered the latest 2022 European Society of Cardiology (ESC) guidelines on VAs as a \"bailout therapy\". Based on preliminary data in the oncology setting, proton therapy could allow further optimization of compliance of these therapeutic doses by preserving even more of the healthy heart part and thus reducing the cardiopulmonary toxicity of radiotherapy outside the ablation target.\n\nThe investigators therefore propose an experimental (prospective interventional) study to evaluate the toxicity (primary endpoint) and efficacy (secondary endpoint) of proton radiosurgery for the treatment of VA with an enrollment of 21 patients. The primary endpoint is to evaluate the toxicity of proton radiotherapy in the acute phase (during the first 30 days of the procedure) and at 3, 6 and 12 months. A crucial part of the protocol will be the proper definition of the target to be irradiated, which will require the integration of different non-invasive cardiac imaging methodologies such as CT (Computed Tomography), MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography), coupled with invasive and\u002For \"non-invasive\" body surface mapping with multi-electrode electrocardiogram (ECG) so as to obtain a \"cardiac image\" in which the myocardial scar and the arrhythmogenic region are fused.",[97,27],"Ventricular Arrhythmia",[99,100,101,102,103],"Stereotactic arrhythmia radioablation (STAR)","Malignant ventricular Tachycardia","Ventricular Tachycardia Storm","Radiotherapy","Proton Therapy","2025-01-23",{"date":106,"type":40},"2025-01-27",{"date":108,"type":20},"2025-02",{"date":110,"type":20},"2030-02",{"name":112,"class":47},"Azienda Sanitaria Universitaria Integrata del Trentino"]